Institutional members access full text with Ovid®

Share this article on:

Procalcitonin Versus C-Reactive Protein for Guiding Antibiotic Therapy in Sepsis: A Randomized Trial*

Oliveira, Carolina F. MD, PhD; Botoni, Fernando A. MD, PhD; Oliveira, Clara R. A. MD, PhD; Silva, Camila B. MD; Pereira, Helena A. MD; Serufo, José C. MD, PhD; Nobre, Vandack MD, PhD

doi: 10.1097/CCM.0b013e31828e969f
Clinical Investigations

Objective: We sought to evaluate whether procalcitonin was superior to C-reactive protein in guiding antibiotic therapy in intensive care patients with sepsis.

Design: Randomized open clinical trial.

Setting: Two university hospitals in Brazil.

Patients: Patients with severe sepsis or septic shock.

Interventions: Patients were randomized in two groups: the procalcitonin group and the C-reactive protein group. Antibiotic therapy was discontinued following a protocol based on serum levels of these markers, according to the allocation group. The procalcitonin group was considered superior if the duration of antibiotic therapy was at least 25% shorter than in the C-reactive protein group. For both groups, at least seven full-days of antibiotic therapy were ensured in patients with Sequential Organ Failure Assessment greater than 10 and/or bacteremia at inclusion, and patients with evident resolution of the infectious process had antibiotics stopped after 7 days, despite biomarkers levels.

Measurements and Main Results: Ninety-four patients were randomized: 49 patients to the procalcitonin group and 45 patients to the C-reactive protein group. The mean age was 59.8 (SD, 16.8) years. The median duration of antibiotic therapy for the first episode of infection was 7.0 (Q1–Q3, 6.0–8.5) days in the procalcitonin group and 6.0 (Q1–Q3, 5.0–7.0) days in the C-reactive protein group (p = 0.13), with a hazard ratio of 1.206 (95% CI, 0.774–1.3; p = 0.13). Overall, protocol overruling occurred in only 13 (13.8%) patients. Twenty-one patients died in each group (p = 0.836).

Conclusions: C-reactive protein was as useful as procalcitonin in reducing antibiotic use in a predominantly medical population of septic patients, causing no apparent harm.s

Supplemental Digital Content is available in the text.

All authors: Graduate Program in Infectious Diseases and Tropical Medicine, Department of Internal Medicine, School of Medicine and Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.

* See also p. 2447.

Currently listed as ClinicalTrials.org (NCT00934011).

Dr. Nobre conceived the study idea. Dr. C. F. Oliveira, Dr. C. R. A. Oliveira, Ms. Silva, and Ms. Pereira acquired the data. Drs. C. F. Oliveira and Nobre analyzed and interpreted the collected data. Drs. C. F. Oliveira, Botoni, C. R. A. Oliveira, and Nobre wrote the manuscript. Drs. C. F. Oliveira, C. R. A. Oliveira, Botoni, Serufo, and Nobre delineated the hypothesis. All the authors reviewed the manuscript prior to submission.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).

Supported, in part, by the Minas Gerais Research Foundation (Fundação de Amparo à Pesquisa do Estado de Minas Gerais, FAPEMIG).

The preliminary results of this study were selected to be presented as oral presentation in the European Society of Intensive Care Medicine 2011 (Abstract A-386-0041-01223). This study was selected to be presented in the poster corner section of the European Society of Intensive Care Medicine 2012 (Abstract A-491-0041-01792).

Dr. Nobre has received payment for lectures from bioMérieux. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: vandack@gmail.com; vandack@medicina.ufmg.br

© 2013 by the Society of Critical Care Medicine and Lippincott Williams & Wilkins